Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
Posted Feb 27 2011 7:00pm
Description of Invention: This invention comprises a number of novel anti-mycobacterial compositions, which offer to significantly improve the treatment of mycobacterial infection such as tuberculosis. Mycobacterium is a genus of bacteria encompassing a number of organisms, many of which are highly pathogenic in humans. The most well known of these are M. tuberculosis, which causes pulmonary tuberculosis, and M. leprae, which causes leprosy. Tuberculosis is a major worldwide problem, especially among HIV-infected and other immune-compromised individuals. Present treatments for tuberculosis often have toxic side effects or have limited utility because of the growing number of multi-drug resistant strains of M. tuberculosis. These newly discovered anti-mycobacterial compounds, which are analogs of thiatetracosanoate, have been shown effective in the treatment of mycobacterial infections and are relatively nontoxic. They may be given alone or in combination with standard anti-mycobacterial drugs and are valuable as antiseptics as well as therapeutics.
For Licensing Information Please Contact: Edward (Tedd) Fenn NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5031 Fax: 301-402-0220